Antibodies are known to damage grafted tissues by a variety of means, so it is important to know how the humoral response is initiated. In this paper we summarise the cellular events in B cell activation, the mechanisms of antibody-mediated rejection and the
IMMUNE RECOGNITION OF TRANSPLANTED TISSUES
The activation of B cells is dependent on T cell help, so first we must consider the activation of T lymphocytes. T cells of the recipient respond to major histocompatibility complex (MHe) molecules which contain a peptidic fragment in a groove on the membrane-distal surface of the molecule (Fig. 2) . Hence, the T cell receptor contacts both the MHC molecule and the bound peptide.
The cytokine-producing T helper cells generally have the CD4 marker on their surface and recognise MHC class II molecules arrayed on the membrane of specialised antigen presenting cells (APe). These APC have the capacity to acquire and degrade foreign proteins and to present the resulting peptides as complexes with MHC class II molecules.
In the case of transplanted tissues which contain a powerful APC population, namely the interstitial The receptors for antigen on the surface of the B lymphocytes are the preformed specific antibodies that the B cell is programmed to make. When a graft is introduced only those clones of recipient B cells with receptors of the appropriate specificity to bind the donor antigen will be triggered to respond. Donor antigens shed from the graft are taken up by the process of receptor-mediated endocytosis and are concentrated within the B cell, where they are degraded to peptide fragments, incorporated into the groove of MHC class II molecules and arrayed on the surface of the B cell as MHC-peptide complexes. Thus, both the APC and the B cells are able to process and present antigen, and the MHC-peptide complexes which appear on the B . cells are also to be found on the APe. In this way a T helper cell activated by the indirect antigen present ing pathway can then interact in a cognate, physical manner through T cell receptor/B cell MHC-peptide conjunction with the B cells able to make anti-donor antibody (Fig. 4) .
The uptake of antigen by a B cell triggers certain metabolic changes which lead to the expression of adhesion molecules and receptors for cytokines, leaving the B cell in a state of partial activation. The B cell-T helper cell contact allows the T cell to signal the B cell to complete its round of activation by (1) providing cytokines such as IL-4 (B cell growth factor or BCGF), IL-5 (B cell differentiation factor I or BCDF 1) and IL-6 (BCDF II), and (2) direct surface-surface interaction of certain adhesion molecule pairs. These 'second signals' are necessary for B cells to develop into antibody-producing plasma cells or memory B cells.
T helper cell cytokines including IFN)' also cause 
ANTIBODY-MEDIATED GRAFT DAMAGE
The mechanisms of antibody action can be classified as simple antigen binding, fixation of complement and binding to Fc receptors (Table I ). An antibody without an Fc region can still bind to 
ANTIBODIES IN GRAFT REJECTION
Different types of graft are known to differ in their susceptibility to antibody-mediated damage (Table II) .
Suspensions of cells or tissues such as bone marrow or isolated pancreatic islets are very vulnerable to complement-mediated lysis and ADCC in vitro. By contrast, it is generally consid ered that antibody plays no role in the rejection of n, number in the group; MST, mean survival time ± standard deviation. Statistical significance was determined using Student's (-test. 
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p=0.012
Corneal allografts from Lewis rats were transplanted to normal DA recipients or to rats in which vascularisation of the graft bed had been induced by the placement of a silk suture.
n, number in the group; MST, median survival time of the graft. Statistical significance was determined using the Mann-Whitney non-parametric U-test.
skin allografts, although there are some well documented situations where this does occur. 6 , 7 The effects of antibody on organ grafts have been most widely examined, but there is still debate about their importance and specificity. Hyperacute rejection is clearly due to preformed anti-donor antibodies in the recipient causing complement fixation in the graft, rapid thrombogen esis and the demise of the transplanted organ within minutes or hours. The damaging antibodies may be 'natural', such as those of the ABO system, or may have been induced, including anti-HLA antibodies induced by rejection of a previous graft, blood transfusions or multiparity. The 'cross-match test' for preformed anti-donor antibodies has largely eliminated the clinical problem of hyperacute rejection. In the developing arena of xenotransplan tation one major barrier to success is the presence of natural antibodies in humans against protein and carbohydrate antigens of animal tissues and the immediate damage that they inflict. Much work is going on to reduce complement levels, to remove these natural antibodies, and to manipulate donor animals genetically either to not express certain target antigens or to be more resistant to comple ment-mediated damage.
Acute rejection is largely a T-cell-mediated process, although a role for antibodies cannot be ruled out. Indeed, antibody can cause acute organ allograft rejection in experimental models. 8 In clinica, practice, declining graft function in the absence of histological evidence of a cellular infiltrate in the graft attracts the diagnosis by default of 'humoral rejection' , and in such cases graft function improves after plasmapheresis to remove 
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Serial serum samples from DA rats grafted with skin or corneas from Lewis rats were tested for the presence of lymphocytoxic anti-donor antibodies. The table shows the day when the antibody response was highest and the maximum titre achieved.
antibodies. Antibodies to HLA antigens and to endothelial and parenchymal cells have been impli cated.
Chronic rejection appears to be a response to endothelial cytomegalovirus cell activation or damage. The causes may be various, including a low-grade cellular reaction or cytomegalovirus infec tion. One putative mechanism is that anti-endothelial cell antibodies activate the endothelium, leading to the release of the growth factors (TGF[3, PDGF, IGF, EGF) involved in tissue repair. The outcome is fibrosis and a concentric vascular intimal prolifera tion resulting in occlusion of the vessels of the graft. 9
ANTIBODIES IN CORNEAL GRAFT REJECTION
Anti-corneal antibodies have been detected after both clinical lO , II and experimen ta1 12 , 13 grafting and, in one clinical case, antibody was apparently the sole mediator of rejection. 14 However, systemic humoral immunity is detected only in some patients, 15 , 16 and in some experimental models no antibody was found. It is not certain whether the antibodies that are formed and are detectable in the serum penetrate the transplanted cornea and, if they do, whether they are responsible for graft damage.
In our laboratory we have studied the acute rejection of rat corneas in the Lewis to DA strain combination (across both major and minor histo compatibility barriers). Some of this work has been published P -19 In this model corneas are rejected in 14 days (Table III , group 1), significantly more slowly than skin grafts (group 5). Skin and cornea share antigens, since sensitisation of recipients with previous skin transplants accelerates the rejection of corneal grafts (group 2). However, rejection of a cornea does not sensitise for accelerated skin graft rejection (group 4). Hence, the cornea is antigenic but is evidently less immunogenic than skin, although this may not necessarily be a property of the tissue itself because corneas transplanted to a prevascu larised graft bed suffer more rapid rejection (Table  IV) . The mechanism of rejection has been studied in this model. As expected, treatment of recipient with anti-CD4 monoclonal antibody delays corneal graft rejection 17 while treatment with anti-CD8 monoclo nal antibody does not (Table V) .
The result of treating with anti-CD4 antibody emphasises the pivotal role of the T helper cell in rejection (see Fig. 1 ) but does not distinguish the mechanism(s) involved. The lack of effect using anti CD8 antibody treatment suggests that cytotoxic T lymphocytes (CTL) are not of major importance. This conclusion is compatible with our observation of the absence of CTL in the spleen or lymph nodes of rats rejecting corneal grafts, in contrast to those rejecting skin. The anti-CD8 antibody result also implies that ADCC is not a major mechanism of graft damage either since the effector cells, LGL, in the rat bear the CD8 marker.
The DA rat does make antibodies to donor antigens after corneal grafting, detected in the serum as lymphocytotoxic activity in the presence of complement (Table VI) .
The maximal antibody response to a skin graft occurs about day 12 after transplantation and reaches a titre in excess of 112000. By comparison the antibody response to a corneal graft is slower and lower, peaking at 3-4 weeks and having a maximum titre of about 11100. At the time of corneal graft rejection no antibody could be detected, and the response peaked 6-8 days after corneal graft rejection.
In summary, then, of the three effector arms of rejection, namely CTL, antibody and infiammation, there is no evidence for CTL activation, the antibody response is too low and too late to account for rejection and ADCC is probably excluded as a major mechanism. Thus, an infiammatory reaction is the most likely cause of corneal rejection in our model and, indeed, we have published evidence showing the presence of CD4 + T cells and macrophages in rejecting corneas, 17 , 18 -although we still cannot exclude a role for low levels of antibody or for the proinfiammatory products of complement activation.
CONCLUSIONS
Antibodies do contribute to graft damage in many situations, but direct evidence for their role in the demise of corneal grafts is scant. In our model of acute corneal allograft rejection the transplant is rejected before the antibody response becomes evident. Perhaps antibodies have a function in chronic rejection of corneal allografts by binding to endothelial cells without killing them, a possibility that deserves further investigation.
